Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2017-10-23 Earnings Release
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: BLC(TM) with Cysview®/Hexvix® real World Data presented at the Société Internationale d'Urologie 2017 Annual meeting
Earnings Release Classification · 85% confidence The document is a press release from Photocure ASA dated October 23, 2017, announcing that data regarding their product BLC(TM) with Cysview®/Hexvix® was presented at a medical conference (Société Internationale d'Urologie 2017 Annual meeting). It details the study findings, includes quotes from the CEO and an investigator, and provides background information on bladder cancer and the product. This format—an announcement of clinical/research findings being presented at an external event—does not fit the strict definitions of 10-K, IR, ER, or CT. It is a general corporate update related to product validation and clinical progress. Since it is not a formal regulatory filing (like 10-K or MRQ) and doesn't fit specific categories like DIV, CAP, or MANG, the most appropriate general category for a non-standard corporate announcement or press release that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous announcements. FY 2017
2017-10-23 English
Photocure ASA: FDA grants priority review for Cysview® supplemental New Drug Application (sNDA)
Regulatory Filings Classification · 100% confidence The document is a press release from Photocure ASA announcing that the FDA has accepted their supplemental New Drug Application (sNDA) for Cysview® on a priority review basis. This type of announcement, detailing regulatory progress, clinical updates, and management commentary, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about regulatory progress and not a comprehensive financial report (like 10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the content focuses heavily on a specific regulatory event (FDA acceptance/priority review) and includes quotes from the CEO, it functions as a material disclosure. While it could be RNS, ERs often cover significant operational/regulatory milestones alongside or instead of pure financial numbers. However, since it is not explicitly tied to quarterly/annual results but rather a specific regulatory event, and it is not a short announcement linking to a full report (RPA), the most appropriate general category for material, non-financial-statement-focused announcements is often RNS, or ER if it's the primary form of disclosure for that period. Given the nature of the announcement (FDA action), it is a significant regulatory disclosure. I will classify it as an Earnings Release (ER) as these often include key operational/regulatory highlights, or RNS as a fallback. Since it is a press release announcing a major regulatory milestone, RNS (Regulatory Filings) is the most accurate general category for non-standard, material disclosures that aren't explicitly defined elsewhere (like DIRS, DIV, etc.). However, many companies issue these types of updates alongside or instead of a formal ER. Given the structure and content (CEO quotes, product background, regulatory news), it strongly resembles an Earnings Release format, even if the core news is regulatory. I will lean towards ER as it is a common format for material updates, but RNS is a close second. Let's re-evaluate: It is a press release about an FDA decision. This is a material event disclosure. It is not a 10-K, IR, or CT. It is not a dividend announcement (DIV) or management change (MANG). It is a specific regulatory update. RNS is the best fit for general regulatory announcements not covered by other specific codes.
2017-10-18 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document text is extremely short (338 characters) and explicitly functions as a 'Financial calendar' announcing a future event: the release date for the 'Quarterly Report - Q3' on 08.11.2017. It does not contain the actual financial data of the Q3 report itself. According to the 'MENU VS MEAL' rule, a document announcing the publication or timing of a report, especially when very brief, should be classified as a Report Publication Announcement (RPA). It is not a full Interim Report (IR) or Earnings Release (ER).
2017-09-12 English
Photocure ASA: Results for second quarter and first half year of 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Second Quarter Report 2017' for the Photocure Group. It contains detailed financial tables (Key figures, EBITDA, revenue breakdowns), operational reviews, and management commentary regarding the company's performance for the period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2017
2017-08-23 English
Photocure ASA: Results for second quarter and first half year of 2017
Investor Presentation Classification · 99% confidence The document is titled "RESULTS FOR SECOND QUARTER AND FIRST HALF YEAR 2017" and contains detailed financial performance metrics, segment breakdowns, income statements, and operational achievements for the specified period (Q2 2017). It includes forward-looking statements, risk factors referencing the Annual Report, and specific financial figures (revenue, EBITDA, expenses). This structure is characteristic of a comprehensive financial report covering a period shorter than a full year, which aligns with the definition of an Interim/Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not the full Annual Report (10-K).
2017-08-23 English
Photocure ASA: Results for second quarter and first half year of 2017
Earnings Release Classification · 100% confidence The document explicitly states it contains the 'Results for second quarter and first half year of 2017' and provides detailed financial metrics (revenue, EBITDA, net profit) for the period. This strongly indicates a comprehensive financial report for a period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it mentions a presentation and includes details about the conference call, the core content is the financial results summary, making IR the primary classification over a mere Report Publication Announcement (RPA). The length (6248 chars) is substantial enough to be the report summary itself, not just a brief announcement. Q2 2017
2017-08-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.